AKTX
Akari Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$9.16
−7.24%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +99.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +11.2%
- EBIT
- +20.2%
- Net income
- +12.6%
- EPS
- +84.3%
- Free cash flow
- +15.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026